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Background: Hypoxia and increased glycolytic activity of tumors are associated with poor prognosis. The purpose
of this study was to investigate differences in radiotherapy (RT) dose painting based on the uptake of 2-deoxy-2-[18 F]-
fluorodeoxyglucose (FDG) and the proposed hypoxia tracer, copper(II)diacetyl-bis(N4)-methylsemithiocarbazone
(Cu-ATSM) using spontaneous clinical canine tumor models.
Methods: Positron emission tomography/computed tomography scans of five spontaneous canine sarcomas and
carcinomas were obtained; FDG on day 1 and 64Cu-ATSM on day 2 and 3 (approx. 3 and 24 hours pi.). Sub-volumes for
dose escalation were defined by a threshold-based method for both tracers and five dose escalation levels were formed
in each sub-volume. Volumetric modulated arc therapy plans were optimized based on the dose escalation regions for
each scan for a total of three dose plans for each dog. The prescription dose for the GTV was 45 Gy (100%) and it was
linearly escalated to a maximum of 150%. The correlations between dose painting plans were analyzed with construction
of dose distribution density maps and quality volume histograms (QVH). Correlation between high-dose regions was
investigated with Dice correlation coefficients.
Results: Comparison of dose plans revealed varying degree of correlation between cases. Some cases displayed a
separation of high-dose regions in the comparison of FDG vs. 64Cu-ATSM dose plans at both time points. Among the
Dice correlation coefficients, the high dose regions showed the lowest degree of agreement, indicating potential
benefit of using multiple tracers for dose painting. QVH analysis revealed that FDG-based dose painting plans
adequately covered approximately 50% of the hypoxic regions.
Conclusion: Radiotherapy plans optimized with the current approach for cut-off values and dose region definitions
based on FDG, 64Cu-ATSM 3 h and 24 h uptake in canine tumors had different localization of the regional dose
escalation levels. This indicates that 64Cu-ATSM at two different time-points and FDG provide different biological
information that has to be taken into account when using the dose painting strategy in radiotherapy treatment
planning.
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Tumor hypoxia has been linked with radiation resistance
since the 1950s, where Gray described a decreased ra-
diosensitivity in oxygen-deprived cells [1]. Since then,
several strategies for identification of hypoxic tumors
have been proposed. Positron emission tomography
(PET) holds a great promise for non-invasive detection
of hypoxia, and various hypoxia specific tracers are in-
vestigated clinically [2-8]. Based on the Pasteur effect
and its hypoxic induction of glycolytic genes, 2-deoxy-2-
[18 F]-fluorodeoxyglucose (FDG) has also been suggested
as a marker of hypoxia [9,10]. Elevated glycolytic activity
and hypoxia are both associated with poor prognosis
and are therefore potential targets for radiation dose es-
calation [3,4,11]. The concept of dose painting was in-
troduced by Ling and colleagues, and is based on the
idea that radio-therapeutic control can be improved by
escalating the dose to tumor sub-volumes with known
radio resistance identified with biological images [12].
The intratumoral distribution of glycolytic activity and
hypoxia may be spatially determined by PET scans with
FDG and the proposed hypoxia tracer, copper(II)diacetyl-
bis(N4)-methylsemithiocarbazone (Cu-ATSM) [10,13,14].
Previous studies in human tumors and experimental
xenografts have identified a potential overlap between
hypoxic regions and glycolytic activity. However, the re-
sults have been varying and the link between FDG up-
take and tumor hypoxia has not been consistent [15-21].
Hypoxia induces an up-regulation of glycolytic activity,
but an increased growth rate also increases glycolytic ac-
tivity and thus increasing the likeliness of regional cellu-
lar expansion beyond the capability of neoangiogenesis,
thus inducing regional hypoxia [22,23]. Situations may
exist where the basic glycolytic activity (Warburg effect)
of the tumor may exceed the capability of hypoxia to in-
duce additional glycolysis (Pasteur effect). The dynamics
of tumor hypoxia can also explain some of the varying
results. Tumor hypoxia occurs as both chronic hypoxia
and acute hypoxia [23], and may therefore influence the
regional overlap of hypoxia and glycolytic activity. Acute
perfusion limited hypoxia may induce cycling hypoxic
changes which may not be validly appreciated by using
glycolytic activity as a marker of hypoxia. Additionally,
cycling hypoxic changes may induce situations where
changes in glycolytic activity may be trailing [24,25].
Dose painting by contours (DPBC) refers to dose es-
calation to a threshold-defined sub-volume within the
tumor. It is an attractive strategy since it is clinically
feasible and standard commercial treatment planning
software can be used [26]. In a previous study we inves-
tigated the overlap between sub-volumes of 64Cu-ATSM
and FDG uptake in a DPBC approach. We showed that
sub-volumes displayed a varying degree of overlap, but
that FDG by this strategy is not a marker of hypoxia, asdefined with 64Cu-ATSM, in RT planning [27]. Given
that both FDG and 64Cu-ATSM are negative prognostic
factors for RT [3,4,28,29], combining the two radio-
tracers in treatment planning seems attractive. However,
including multiple tracers in a biological target volume
(BTV) only allows a limited dose escalation as the BTV
then represents a large fraction of the gross tumor volume
(GTV). In order to target both tracers, a more sophisti-
cated dose prescription that allows a highly conformal
dose delivery with possibilities for redistribution of dose is
required. Bentzen proposed a new aspect of dose painting
by the introduction of “dose painting by numbers”
(DPBN) in 2005 [30]. This strategy accommodates the
problem of binary volumes in DPBC, and allows a linear
relationship between PET uptake and prescribed dose,
which is biologically more intuitive and where higher peak
doses can be achieved [26]. However, the voxel-based
treatment planning is complex and special software is re-
quired. Planning and delivery of a complex dose painting
case has previously been proven feasible using volumetric
modulated arc therapy (VMAT), (RapidArc, Varian Med-
ical Systems, Palo Alto, US) [31].
This study investigates the influence of the correlation
between glycolytic activity and hypoxia for RT planning
in spontaneous canine tumors. Based on our previous
findings it seems attractive to include the intersection
volume between FDG and 64Cu-ATSM in the target vol-
ume. The intersection volume constitutes a relatively
small fraction of the total GTV and thus allows a sub-
stantial dose increase compared to the BTV [27]. How-
ever, this strategy is only valuable if high-uptake regions
for FDG and 64Cu-ATSM are co-localized within the
intersection volume.
The aim of this study is to evaluate and compare RT
dose painting plans based on a DPBN approach for PET
scans of FDG and 64Cu-ATSM at two different time
points post injection. Standard commercial treatment
planning software is used for this dose escalation strat-
egy where five dose escalation levels are defined from
PET uptake within the GTV.
Furthermore, we investigate if a dose painting plan
based on FDG-uptake can replace a hypoxia-guided
64Cu-ATSM-based dose painting plan by analysis of
quality volume histograms (QVH).
Methods
Tumor imaging and image reconstruction
PET/CT data from five spontaneous canine cancer pa-
tients with sarcomas or carcinomas were included in this
planning study in accordance with a previously de-
scribed protocol approved by the local ethics committee
[32]. All dogs were scanned with baseline FDG PET/CT
on day 1 (approx. 1 h p.i.) and 64Cu-ATSM PET/CT on
day 2 and 3, approx. 3 h and 24 h p.i. A mean activity of
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anaesthetized and immobilized during the scanning pro-
cedure to ensure comparable images. Scanning and re-
construction parameters were described in a previous
study [27].
Target volume definition
PET/CT images were transferred to Eclipse v10 treat-
ment planning software (Varian Medical Systems, Palo
Alto, CA, US). The gross tumor volume (GTV) was de-
lineated by a veterinarian and an experienced radiologist
and on the day 1 CT. Images were manually co-registered
in Image Registration (Varian Medical Systems, Palo Alto,
CA, US) with 3 h 64Cu-ATSM (day 2) as the reference
image.
The high-risk sub-volume of each tumor was defined
by thresholding of standardized uptake values (SUV) in
a DPBC approach as previously described [27]. The cut
off value for FDG was 40% of SUVmax [33], whereas the
3 h 64Cu-ATSM sub-volume (Cu3) was defined by an
absolute SUV of 1.4, reflecting tumor hypoxia defined by
an oxygen tension below 10 mmHg [34].
No previous studies have defined a cut off value for long
distribution times of 64Cu-ATSM, and tumor-to-muscle
ratio was therefore used for calculation of the cut off
value for the 24 h 64Cu-ATSM (Cu24) sub-volumes. In
order to reach a higher peak dose, the dose prescription
was based on a DPBN related method and five dose es-
calation levels were defined within the high-risk sub-
volume. For each dose level, a target substructure was
created in Eclipse for dose optimization (DP1-DP5 from
low to high dose). The segmentation of PET images
was performed at a Leonardo Workstation (Siemens,
Erlangen, Germany), and dose levels were defined based
on the assumption that PET uptake and radiosensitivity
display a linear association.
Dose prescription
A DPBN approach with a linear escalation to the target
was used for dose prescription. However, due to the seg-
mentation into five dose levels, dose delivery is only an
approximation of this linear relationship. At our institu-
tion the standard pre-operative RT protocol for canine
cancer patients with soft tissue sarcoma is 4.5 Gy in 10
fractions, 3 fractions per week, which was used for dose
prescription in this planning study. The GTV received
100% of the prescribed dose, and radiation dose was es-
calated to the five dose levels with the high-uptake re-
gion receiving a maximum of 150%. This dose escalation
has previously been associated with an increased tumor
control probability (TCP) [35].
The first dose escalation level for each PET scan was de-
termined by a DPBC cut-off value as mentioned above.
The cut-off values were either a percentage of SUVmax(FDG) or an absolute uptake value (64Cu-ATSM). All
values for the first dose levels (DP1) were calculated as a
percentage of the maximum uptake given as ‘SUVc’ in the
dose prescription equation beneath. The dose for each
dose level was calculated based on the mean value be-
tween cut-off values for two neighboring dose levels,
‘SUViso’:
Dose %ð Þ ¼ 100þ SUV iso − SUV c
100 − SUV c
 50;
Treatment planning
RapidArc plans using 6 MV photons and a multi leaf
collimator with 2.5 mm leaf width were optimized based
on the dose escalation regions for each tracer for a total
of three dose plans for each dog. All treatment plans
were constructed with two arcs and complementary col-
limator rotation angles of 45 and 315 degrees were used.
The dose plan was optimized with upper and lower dose
limits for each target substructure, securing the calcu-
lated dose for the respective dose level. All substructures
were prioritized equally and no dose-constraints were
applied for organs at risk. For accurate modeling of dose
deposition in the heterogeneous target with small dose
regions, the anisotropic analytical algorithm (AAA) was
used as calculation model with a 1 mm grid.Correlation of dose painting plans
For all GTVs, the dose in Gy per voxel was analyzed in
MATLAB (R2009b, MathWorks, Natick, MA, US) and
treatment plans based on FDG and 64Cu-ATSM at 3 h
and 24 h p.i. were compared based on 2D histograms.
To analyze whether an FDG-based dose painting plan
can sufficiently cover tumor hypoxia assessed by the up-
take of 64Cu-ATSM, QVH between FDG and 64Cu-
ATSM plans were constructed. QVHs resemble the dose
volume histograms and are in this study obtained by cal-
culation of the ratio between the planned dose for FDG
and the planned dose for 64Cu-ATSM at both time
points. The QVH reflects the plan conformity, and a
steep curve with a quality index (QI) of 1 resembled a
perfect match between the two plans; a value between
0.95 and 1.05 was considered satisfactory. QVHs were
produced for the entire GTV in order to assess the qual-
ity of the following comparisons of plans: FDG vs. Cu3,
FDG vs. Cu24 and Cu3 vs. Cu24. The latter QVH was
assessed due to the previously described temporal differ-
ences in the uptake of 64Cu-ATSM [32]. The co-
localization of high-dose regions in all dose painting
plans was analyzed by calculation of the Dice correlation
coefficient for each dose level.
Table 1 Tumor characteristics, sub-volume data and SUV
Dog no. Tumor type Tumor localization GTV (ccm) FDG (ccm) Cu3 (ccm) Cu24 (ccm) SUVmax FDG SUVmax Cu3
1 Hemangiopericytoma Lumbar region 128.7 13.0 85.8 61.6 7.9 2.3
2 Fibrosarcoma Lat. cervical region 88.2 66.4 63.9 17.0 8.5 3.6
3 Squamous cell carcinoma Nasal cavity 55.4 23.7 21.2 30.0 23.1 3.0
4 Adenocarcinoma Nasopharynx 20.8 10.3 9.3 3.5 13.2 2.5
5 Undifferentiated soft tissue sarcoma Mandible 23.2 11.2 6.2 0.6 9.7 2.6
Avg. 63.3 24.9 37.3 22.5 12.5 2.8
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Patient characteristics, sub-volume sizes and SUV are
given in Table 1. The mean SUV for Cu3 was 2.8 (range:
2.3-3.6) and the cut off for Cu3 at SUV 1.4 therefore
corresponds to an approximated 50% of SUVmax, which
is a frequently used threshold for other PET tracers.
Dose prescription was calculated based on PET-uptake
as described above, and the following mean doses (range)
were prescribed to dose levels: DP1 47.3 Gy (47.1-47.5),
DP2 51.8 Gy (51.5-52.0), DP3 56.3 Gy (56.1-56.3), DP4
60.7 Gy (60.3-60.8) and DP5 65.3 Gy (65.2-65.3). Table 2
shows the mean volumes of all dose levels for FDG, Cu3
and Cu24.
In six treatment plans, the highest dose level (DP5)
could not be transferred to the treatment planning sys-
tem, since the substructure was present at only one slice
of the CT scan and therefore not a potential volume for
VMAT optimization. The DP5 substructure was lost in
four out of five cases for the Cu24 dose plan and in two
cases for Cu3. None of the FDG substructures were lost
in the transfer to treatment planning. The transfer of
contours and volumes between software caused volu-
metric estimates to be somewhat dissimilar (Tables 1
and 2). All contours were visually inspected in both Leo-
nardo Workstation and Eclipse, and the geometrical dif-
ferences were found to be inconsequential for the
purpose of dose painting and treatment planning.
The comparison of dose painting plans was based on
the assumption that the GTV did not change anatomic-
ally in between the scans. The 2D histograms in Figure 1
illustrate a large variation in the correlation of dose
painting plans for each dog. There is a general trend for
a more linear correlation between Cu3 and Cu24, whereas
FDG vs. Cu3 and Cu24 in some cases show a distinct sep-
aration of the high-dose areas. In all cases, a high intensityTable 2 Dose level volumes (mean values)
Dose level FDG (ccm) Cu3 (ccm) Cu24 (ccm)
DP1 8.56 12.69 7.73
DP2 6.02 8.51 3.03
DP3 4.14 3.45 0.61
DP4 1.64 1.13 0.09
DP5 0.19 0.17 0.00of dose is observed at 45 Gy, which is the base dose deliv-
ered to the total GTV. Correlations of PET-uptake within
the total GTV are similar to the 2D histograms (data not
shown).
QVH analysis to assess the feasibility of covering a
hypoxia-guided target based on FDG dose painting is
depicted in Figure 2A. In some cases it is possible to
achieve an acceptable coverage for a relatively large per-
centage of voxels. As described above, the treatment
plan was considered satisfactory with a QI between 0.95
and 1.05. This is obtained for approximately 50% of vox-
els for comparisons of FDG and 64Cu-ATSM, whereas
the association between Cu3 vs. Cu24 displays a better
coverage with 60% of the voxels having a sufficient QI
(Table 3).
Figure 2B illustrates Dice correlation coefficients for
each dose level of FDG vs. Cu3 and Cu24. It shows vari-
ation between cases, but a clear trend for an increasing
mismatch between dose painting plans with higher dose
levels is observed. In general, the steepness of the coeffi-
cient drop is greater for FDG vs. Cu24. Correlation coef-
ficients for the comparison of Cu3 and Cu24 also display
varying results between cases. The probability for correl-
ation between dose levels reflected by Dice correlation
coefficients naturally decreases with decreasing volume
of dose levels.
Discussion
In this study, highly heterogeneous dose painting plans
based on FDG and 64Cu-ATSM were compared in order
to assess whether an FDG-based treatment plan could
sufficiently cover tumor hypoxia and thereby replace
64Cu-ATSM based dose painting.
Comparison of dose plans using 2D histograms revealed
a mismatch between treatment plans based on FDG and
64Cu-ATSM (3h and 24h pi.). Some cases displayed a cor-
relation pattern indicating no overlap between the high-
dose regions. The high-dose regions showed the lowest
degree of agreement, indicating that inclusion of com-
bined information from multiple tracers for dose painting
may improve therapeutic benefit. These findings were pri-
marily observed in the correlation between FDG and
64Cu-ATSM treatment plans at both time points. There
was a tendency towards a stronger correlation between
Figure 1 2D histograms for comparison of dose painting plans.
A comparison of FDG and 64Cu-ATSM dose painting plans showing
diverging results. The FDG and Cu3 2D histograms tend to display a
separation of the high-dose areas indicating an increasing mismatch
at the high-dose levels and therefore a poor degree of overlap
between the dose plans. The dose is distributed with an even
greater variation when comparing FDG and Cu24. The two dose
painting plans based on early and late 64Cu-ATSM demonstrate an
improved correlation compared to FDG vs. 64Cu-ATSM, however
linearity is not observed.
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bution time is less important than the PET tracer used for
phenotypical characterization of the tumor.
Previous studies have compared the overlap between
FDG-uptake and hypoxia by imaging comparisons, auto-
radiography and gene expression analyses with inconclusive
results [10,15-17,20,32,36]. Including tumor physiologic
aspects assessed by PET in treatment planning seems at-
tractive, and may potentially lead to improved tumor con-
trol if a clinically feasible and a reproducible technique is
established. Validation of the proposed PET tracers includ-
ing the combined information is the first step of this
process, while clarifying how the PET signal is translated
into RT target volumes in a clinically relevant and robust
approach is the second step. Considering the scale on
which changes in the tumor microenvironment occur, the
spatial resolution of the PET system is poor. One voxel
may represent a wide variety of oxygen tensions, and con-
verting the PET signal from numerous voxels within a
tumor to dose painting targets will inevitably lead to loss
of information [37-39]. In regards to the overlap between
FDG and 64Cu-ATSM, the question is whether this loss of
information results in a smoothing of differences or even
larger mismatches between the tracers. A heterogeneous
uptake of both PET tracers may indicate that hypoxic re-
gions are missed when treatment optimization is based on
FDG only. In this study, PET images and 2D histograms
displayed similar correlation patterns indicating that treat-
ment planning based on defined dose levels does not
cause significant loss of PET information.
FDG is the most frequently clinically used PET tracer
and high uptake is associated with several malignant
characteristics including increased growth rate and hyp-
oxia [10]. It therefore seems attractive to include only
FDG-avid regions in RT planning. However, the strong
prognostic effect of tumor hypoxia and the increased
evidence that FDG uptake does not sufficiently include
hypoxia makes multi-tracer RT planning attractive. In
this study, we explored the possibilities for applying an
FDG-based dose-painting plan on tumor hypoxia assessed
by the uptake of 64Cu-ATSM. QVH analysis revealed
that an acceptable coverage of hypoxic regions could
be obtained for only approximately 50% of the voxels
Figure 2 QVH (A) and Dice correlation coefficient (B). Comparison of dose painting plans: FDG vs. Cu3, FDG vs. Cu24 and Cu3 vs. Cu24. The
Dice correlation coefficient decreases with increasing dose level, and no correlation is observed for the high-dose regions.
Clausen et al. Radiation Oncology 2014, 9:228 Page 6 of 8
http://www.ro-journal.com/content/9/1/228emphasizing the need for alternative strategies in hypoxia-
guided RT.
This is to our knowledge the first study to compare
dose painting treatment plans based on two PET-tracers.
In a previous study on the same group of canine cancer
patients, we observed an overlap between FDG and
64Cu-ATSM based on a DPBC approach [27]. However,
dose escalation to a target volume including both PET
tracers in a BTV was not feasible, as the volumes repre-
sented a large fraction of the GTV and therefore could
lead to increased toxicity. Targeting the intersection vol-
ume between FDG and 64Cu-ATSM would allow inclu-
sion of both tracers for DPBC treatment planning. The
feasibility of increasing tumor control by this strategy re-
quires co-localization of high-dose regions within the
intersection volume. Calculation of Dice correlation co-
efficients revealed an increasing mismatch between FDG
and 64Cu-ATSM dose painting plans; the higher dose re-
gion, the larger mismatch. However, these data must beTable 3 The fraction of voxels with an acceptable QI
Dog no. FDG vs. Cu3 FDG vs. Cu24 Cu3 vs. Cu24
1 0.40 0.57 0.53
2 0.34 0.27 0.48
3 0.64 0.56 0.67
4 0.52 0.68 0.56
5 0.58 0.56 0.80
Mean 0.49 0.53 0.61carefully interpreted as the very small high-dose regions
lower the likelihood of an intersection volume to exist.
A poor correlation between the high-dose regions of
FDG and 64Cu-ATSM can still allow the targeting of
both tracers in a DPBC approach, as the small volumes
may be co-localized within the intersection volume. Fur-
thermore, it is important to mention the influence of the
chosen thresholds in this study. The highest dose level,
DP5, could not be transferred to the dose planning soft-
ware in four of five cases for Cu24, and the structure
was also lost in two cases for Cu3. If a different thresh-
old had been chosen, these results might have differed.
However, the trend for a lower degree of correlation be-
tween the high dose areas seems clear.
The dose level volumes of Cu24 are generally smaller
than those of FDG and Cu3, which may explain the
poorer correlation between FDG and Cu24.
The delivery of heterogeneous dose distribution with
standard treatment planning software has been proven
technically feasible [31] and modeling studies also sug-
gest that biologically adapted RT can lead to large im-
provements in TCP [40-43]. However, several open and
unanswered questions still need to be clarified before clin-
ical implementation. The clinical feasibility of hypoxia-
guided dose painting is highly dependent on a robust
target throughout the treatment course as a mismatch be-
tween delivered dose and hypoxic regions potentially re-
sult in decreased tumor control. Tumor hypoxia is known
to be a dynamic and clinical observations of tumor
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within minutes, hours or even days [39]. It has been
shown that relatively large regions within tumors exhibit
transient periods of hypoxia and reoxygenation [44],
which is also reflected by the studies of pretreatment
tumor hypoxia reproducibility [45,46]. Voxel-by-voxel cor-
relations previously done on this series of PET/CT scans
displayed temporal changes in the uptake of 64Cu-ATSM
suggesting that hypoxia-guided dose painting treatment
plans may vary markedly dependent on time point [32].
Hypoxia-guided dose painting therefore requires further
evaluation of the temporal stability of tumor hypoxia and
the need for adapted treatment during the course of RT.
The delivery of highly heterogeneous dose distributions
also demands tumor movement to be taken into account;
especially in this DPBN based strategy with complex and
often small target volumes where margins cannot be
added.
There are several drawbacks to this planning study in-
cluding a low number of cases with varying histopathol-
ogies. In our study, no trend was observed between
histopathology and the correlation of FDG and 64Cu –
ATSM, however, in a larger material, a difference be-
tween sarcomas and carcinomas may be observed. The
segmentation method and the threshold-based treatment
planning may also influence the observed correlations
between FDG and 64Cu-ATSM dose painting plans; es-
pecially the thresholding of late 64Cu-ATSM PET must
cautiously interpreted as no previous studies have de-
scribed a cut-off value for tumor hypoxia at 24 p.i. As
mentioned above, the Dice correlation coefficients are
affected by the size of the analyzed volumes and poorer
correlations are therefore expected for small volumes,
and co-localization of high-dose regions in the intersec-
tion volume cannot be excluded.
This study must be considered exploratory due to the
drawbacks mentioned above, including the thresholding,
which may influence the obtained results. The low de-
gree of overlap between high-dose regions may therefore
be explained by the chosen threshold procedure, and
further studies are needed in order to draw any firm
conclusions.
Conclusion
The correlation analysis of dose plans based on FDG,
64Cu-ATSM 3 h and 24 h uptake in canine tumors
showed that regional dose escalation levels have different
localizations based on the current approach for cut-off
values and dose region definition. This indicates that
64Cu-ATSM at two different time-points and FDG pro-
vide different biological information that has to be taken
into account when applying the dose painting strategy in
RT planning. Based on current knowledge with poor
prognosis being related to both hyperglycolysis andhypoxia and the result from this study where only a par-
tial overlap is observed between FDG and 64Cu-ATSM,
the inclusion of multiple tracers in RT planning seems
attractive. In such strategy, a number of boost levels
within each high-risk sub-volume will be the most at-
tractive approach in order to improve tumor control as
the localization of high-uptake regions are different for
the two tracers.
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